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Objectives: Succinic acid as endogenous metabolite, has a wide range of applica-
tions in medical care. We conduct research on the development of new medicines 
based on succinic acid, ascorbic acid and rutin for the prevention and treatment of 
influenza. A systematic review was carried out to perform a qualitative assessment 
of succinic acid adding in the various medicines and to determine of their phar-
macological action. MethOds: MEDLINE®, EMBASE®, Scopus, Cochrane Library 
databases and clinical trials registers between 1966 and Jun 2015 were performed. 
To analyze the RCT were selected and Review on the Study of the pharmacological 
action of drugs, which include succinic acid. Quality of evidence was assessed and 
each article was rated of quality. Results: Our study included 29 articles (23 RCT 
and 6 Review). The evidence varied in terms of: scope and years of research, type 
of treatment, study duration, sample size (< 100 to> 500 patients). Generally, the 
mean age of included patients was middle. For pharmacological properties and by 
relevance RCT are grouped as follows: antigypoxic action were 7 RCT (2003-2013 
years), improve iron absorption in the gastrointestinal tract - 6 RCT (1966-1974), 
hepatoprotective - 4 RCT (2013-2014 years). One RCT proves the efficiency of suc-
cinic acid used in gastroenterology (a combination with omeprazole, 2012), depres-
sion (2013), in transplantation (1993) at menopause (2008), renal failure (2013), to 
improve body temperature during surgery (2007). Analysis of Review opens the new 
prospects for the use of succinic acid in cancer, diabetes and hepatitis C treat-
ment. cOnclusiOns: A comprehencive overview of these studies estimated the 
evidence of succinic acid addition of the drugs. Succinic acid as endogenous metabo-
lite, is a part of drugs of different pharmacological actions. These clinical trial results 
have been retrieved and give the possibility to develop of new drugs with succinic 
acid also in Ukraine.
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bAckgROund: The Parkinson’s Kinetigraph (PKG) is the first device that objec-
tively measures treatable Parkinson’s Disease (PD) symptoms in daily living. 
Collected symptom scores – Bradykinesia [BKS], Dyskinesia [DKS], and Fluctuation 
[FDS] – have been validated and correlate with PD reference standard instru-
ments (UPDRS, AIMS, Patient Diaries). The PKG is used globally – in Europe, 
Asia-Pacific, and the USA. There is a de-identified central repository of all PKG 
reports. Objectives: Using the central repository, to assess whether patients 
who received a PKG analysis in routine care featured improved PD symptom scores 
over time. MethOds: PD patients who had 2+ PKGs within a 6-month time frame 
were eligible for analysis. A total of 591 patients were included and split into 
“controlled” and “uncontrolled” at baseline (first PKG), based on pre-defined cut-
off scores for BKS (23) or DKS (5); for FDS, a normal range was defined, above and 
below which patients were considered uncontrolled. The Mann-Whitey U test 
was used for analysis. Results: For those patients featuring scores considered 
“uncontrolled” (BKS high, DKS high, FDS low or high) at baseline, a statistically and 
clinically significant improvement, on average, was recorded for that score in their 
second PKG in all 4 subgroups (p< 0.01). For those patients with uncontrolled FDS 
at baseline, 43% (FDS low) and 34% (FDS high) had scores considered controlled 
in their second PKG; regarding high DKS, 69% showed some improvement. All 
improved scores were sustained or somewhat augmented on average in those 
patients having more than 2 PKGs. cOnclusiOns: The analysis suggests that 
adding a PKG to a PD patient’s therapy management may significantly improve, 
and subsequently sustain, patient PD scores over time. This is important as, due 
to natural PD progression, one would expect PKG symptom scores to deteriorate 
over time. Other potential PKG benefits were not part of this analysis.
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Objectives: Spasticity is one of the well-recognized complications of stroke which 
may give rise to pain and limit patients’ ability to perform daily activities. The pre-
disposing factors and direct effects of post-stroke spasticity (PSS) also involve high 
management costs in terms of healthcare resources and case-control designs are 
required for establishing such differences. In ‘The Health Improvement Network’ 
(THIN) database, such a study was difficult to provide reliable estimates since the 
prevalence of post-stroke spasticity was found to be substantially below the most 
conservative previously reported estimates. The objective of this study was to use 
predictive analysis techniques to determine if there were a substantial number of 
potentially under-recorded patients with PSS. MethOds: This study used retrospec-
tive data from adult patients with a diagnostic code for stroke between 2007 and 
2011 registered in THIN. Two algorithm approaches were developed: 1) a statistically 
validated data-trained algorithm using machine techniques and 82 potential predic-
tors; and 2) a clinician-trained algorithm based on the review of 200 stroke cases 
by two expert neurologists. The algorithm with the better performance was used 
to identify PSS cases. Results: In THIN data, 45,613 stroke events were identified, 
with 660 having a diagnosis PSS. A data-trained algorithm using Random Forest 
showed better prediction performance than the clinician-trained algorithm, with 
higher sensitivity and only marginally lower specificity. Overall accuracy was 84% 
and 72%, respectively. The data-trained algorithm predicted an additional 3,912 
records consistent with patients developing spasticity in the 12 months following a 
stroke. cOnclusiOns: Using machine learning techniques, additional unrecorded 
post-stroke spasticity patients were identified, increasing the condition’s prevalence 
was the primary endpoint, and compared the assessments. Results: Guidance from 
regulatory and HTA agencies indicates the suitability of PFS as an endpoint depends 
on the cancer type and stage, seen in assessments of afatinib and erlotinib in non-
small cell lung cancer and bevacizumab in ovarian cancer: FDA and EMA approvals 
were based on PFS data. However, the TC in France awarded ASMR IV for erlotinib and 
bevacizumab and ASMR V for afatinib. NICE in the UK approved afatinib and erlotinib 
based on additional interim OS data and a patient access scheme; bevacizumab was 
not approved because of uncertainty in translating PFS gain to OS. cOnclusiOns: 
PFS is a valid and credible endpoint in many oncology trials. However, differences 
in stakeholder perspectives and evidentiary requirements may mean that products 
approved on the basis of PFS data face delays in HTA or protracted pricing negotia-
tions, or are rejected for reimbursement. PFS as an endpoint allows shorter trials , 
efficiency is improved, and fewer patients are exposed to an investigational drug. 
The limitations associated with PFS as an endpoint are largely manageable. Thus, the 
value and relevance of PFS needs to be recognized consistently across HTA agencies, 
and approaches harmonized between HTA agencies and regulators.
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Objectives: To elicit a comprehensive stakeholder view on the acceptability of using 
real-world evidence (RWE) for informing trial design and establishing relative effec-
tiveness (RE) of new medicines in regulatory and HTA assessments. MethOds: IMI 
GetReal (www.imi-getreal.eu) is facilitating stakeholder dialogue on the role of RWE 
through case studies which focus on RE issues in several disease areas. In a series of 
pilot workshops, stakeholders considered challenges in establishing the RE of multiple 
sclerosis (MS) medicines. Alternative solutions were proposed for using RWE to miti-
gate these challenges: participants provided views on the usefulness and acceptability 
of solutions and the potential impact on regulatory and reimbursement decision 
making. Results: Three approaches were proposed: 1) supplementing trial results 
with RWE in network meta-analysis (NMA) to generate RE estimates; 2) incorporating 
RWE in NMA to support simulations informing trial designs; 3) using risk equations 
derived from RWE to inform risk stratified trial designs. Stakeholders cautiously wel-
comed the proposals as additional options for reducing decision-making uncertainty, 
raising the key issue of potential biases that could be introduced by including RWE in 
these ways. The inclusion of RWE would most likely be considered as supportive of or 
adding context to regulatory submissions, but could be more central in HTA decision 
making and early medicine development if appropriate quality control measures 
are put in place to mitigate biases commonly associated with non-interventional 
data. cOnclusiOns: For the use of RWE to become more acceptable by decision mak-
ers, standard methods for data synthesis should be developed, as well as guidelines 
to ensure transparency in selection of data sources and data synthesis. The GetReal 
consortium provides a ‘safe harbour’ for stakeholders to discuss the potential use of 
RWE for decision making, and further work is ongoing to develop methods for the 
‘early’ use of RWE and to foster dialogue between stakeholders.
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Objectives: Objective of this study was to provide a baseline against which 
to monitor trends in breast cancer awareness and the effect of interventions to 
promote breast cancer awareness. MethOds: A cross sectional house hold survey 
was conducted on 365 young women between the age group of 18-40 in urban and 
rural areas of South India using a validated questionnaire. Results: A total of 99% 
respondents knew that breast cancer is the leading cancer with a mean knowl-
edge of 73.7±15.1% for urban and 47.2±13.9% for rural women. Sources of infor-
mation for their knowledge were mainly health professionals/workers (98.2%), 
friends/neighbors (83.5%), TV/Radio (76.0%) and printed materials (60.2%). Rural 
women had significantly less awareness compared to urban women. Majority 
of the respondents knew the risk factors of breast cancer aging (69%), nullipar-
ity (56.4%), delivery at more than 30 years old (46%), shorter duration of breast 
feeding (72.0%), contraceptive pills (46.0%), obesity (80.0%), big breast (81%), hor-
mone replacement therapy (HRT) (54.4%), menopause after the age of 50 (20%) and 
menarche before age 11(34.8%). most of the respondents agreed that the following 
are risk factors smoking (85.2%), alcohol intake (86.8%) and exposure to radiation 
(67.2%).the rural respondents strongly believed that breast cancer with wearing 
of underwire bra (34.3%) but most of the urban respondents not believed (65.6%).
Regarding awareness of the screening methods, 66% and 49% were aware about 
BSE and CBE respectively, 78% were aware about mammography. cOnclusiOns: 
The study showed awareness of breast cancer and practice of screening procedures 
increases with higher education and urban living. Therefore, there is an urgent 
need to conduct breast cancer awareness camps in rural areas for an intensive 
breast cancer awareness campaign and availability of screening centers prioritized 
in rural areas.
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